{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreiazcqxi4c75hfwvwk3uqc6o4zc7j3jqeg7nqxuqgtuhri27lrhnf4",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3mmck7kysued2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreiga7rq76r72wa3axfdn62er2rwv63bymzuc773vchqgtw4lmmacs4"
    },
    "mimeType": "image/jpeg",
    "size": 86823
  },
  "path": "/2026/05/20/rare-disease-biotech-ceos-discuss-fda-uncertainty-stat-summit/?utm_campaign=rss",
  "publishedAt": "2026-05-20T17:00:07.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "Biotech",
    "Politics",
    "biotechnology",
    "Pharmaceuticals",
    "STAT+",
    "STAT Summit"
  ],
  "textContent": "How the ouster of key officials at the FDA has created anxiety and uncertainty for the developers of rare disease drugs.",
  "title": "STAT+: Biotech execs, academic expert lament impact of FDA turnover on rare disease drug development",
  "updatedAt": "2026-05-20T17:00:12.000Z"
}